Sign in

    Christopher Marai

    Managing Director and Senior Equity Analyst at Nomura Securities Co. Ltd.

    Christopher Marai is a Managing Director and Senior Equity Analyst at Nomura Securities Co. Ltd., specializing in healthcare with a focus on biotechnology and drug manufacturers. He covers companies such as BeyondSpring, Sarepta Therapeutics, Syndax Pharmaceuticals, and Prothena Corporation, and has a documented performance track record with a 51.61% success rate and an average return of 10.77%, ranking him #2,370 out of 4,884 analysts. Marai began his tenure at Nomura in September 2016 after serving as a biotech analyst at Oppenheimer & Co., holding a Ph.D. and maintaining FINRA registration with multiple securities licenses. His notable achievements include generating outsized returns on certain calls, reflected in TipRanks and other analyst performance platforms.

    Christopher Marai's questions to Protagonist Therapeutics (PTGX) leadership

    Christopher Marai's questions to Protagonist Therapeutics (PTGX) leadership • Q4 2019

    Question

    Christopher Marai of Nomura Securities Co. Ltd. inquired about the development of PTG-300, specifically asking about its use in non-transfusion-dependent beta-thalassemia patients, the company's capacity to run multiple registration trials in 2021, and how the established dose for beta-thalassemia might inform dosing for polycythemia vera (PV) and hereditary hemochromatosis (HH).

    Answer

    President and CEO Dinesh Patel confirmed that the non-transfusion-dependent patient population is still being pursued, though enrollment is slow as expected. He clarified that the immediate goal is to select the first, not necessarily the only, indication for a pivotal study. Mr. Patel explained that since transfusion-dependent beta-thalassemia has the highest iron burden, the effective doses for PV and HH are logically expected to be the same or lower. The company has tested up to 80 mg weekly and has the safety coverage to go higher if needed.

    Ask Fintool Equity Research AI